HBIO
Harvard Bioscience·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Consensus Rating "Strong Buy"
High Gross Profit Margin
Price Hits 52-week Low
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HBIO
Harvard Bioscience, Inc.
A developer of life sciences equipment to support research and drug discovery
Life Science Tools and Services
--
12/07/2000
NASDAQ Stock Exchange
330
12-31
Common stock
84 October Hill Road, Holliston, Massachusetts 01746
--
Harvard Bioscience, Inc., was incorporated in Delaware in 1901. The Company is a leading developer, manufacturer and marketer of technologies, products and services that enable fundamental progress in life science applications, including research, pharmaceutical and therapeutic discovery, biological production, and preclinical testing for pharmaceutical and therapeutic development.
Earnings Call
Q3/2025
Estimate EPS0
Actual EPS-0.03
Estimate Revenue20.00M
Actual Revenue20.60M
Harvard Bioscience's Q3 2025: Contradictions Emerge on NIH Funding Timing, Academic Funding Visibility, Preclinical Sales Growth, and Government Shutdown Impact
Nov 07,2025 02:29
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
HBIO has released its 2025 Q3 earnings. EPS was reported at -0.03, versus the expected 0, missing expectations. The chart below visualizes how HBIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HBIO has released its 2025 Q3 earnings report, with revenue of 20.59M, reflecting a YoY change of -6.28%, and net profit of -1.23M, showing a YoY change of 74.36%. The Sankey diagram below clearly presents HBIO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
